Clinical-stage immuno-oncology company Agenus (NASDAQ:AGEN) recently executed a 1-for-20 reverse stock split to give the ...

Baird raised the price target for the Agenus Inc (NASDAQ:AGEN) stock to “an Outperform”. The rating was released on June 06, 2023, according to finviz. We previously noted in another research note ...

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.

Build your portfolio and react to the markets in real time. Compete against your friends or coworkers to earn your spot at the top of the leaderboards. If you are a teacher, professor or ...

Investors considering a purchase of Agenus Inc (Symbol: AGEN) stock, but tentative about paying the going market price of $7.08/share, might benefit from considering selling puts among the ...

(RTTNews) - Agenus Inc. (AGEN) stock is falling over 14 percent on Friday morning after the announcement of updated data from its phase 1 clinical trial of BOT/BAL combination therapy in patients ...

Small-Cap Cancer Drug Developer Agenus' Highlights Encouraging Data From Colorectal Cancer, But Funding Concerns Loom The latest Phase 1 trial results of Agenus' botensilimab and balstilimab (BOT ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...